|
|
Article: Outlook 2002: M&A in the biotech sector could spell consolidation. (Markets: Pharmaceuticals & Fine Chemicals).(Statistical Data Included)
- Article from:
- Chemical Market Reporter
- Article date:
- January 7, 2002
- Author:
CopyrightCOPYRIGHT 2002 Schnell Publishing Company, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AFTER THE SHAKE-UP of 2000, the fine chemicals industry spent 2001 in a fairly quiet state. Companies digested the major acquisitions from the prior year, turned primarily toward organic means of strengthening their businesses and made small, targeted, technology-focused purchases.
But the recent run of M&A in the biotech industry could signal further consolidation in pharmaceutical fine chemicals. As biotech firms become more financially sound, either because their products start to generate sales revenues, through mergers or by aligning with big pharma, contract manufacturing organizations (CMOs) are likely to encounter both challenges and opportunities from the ...